Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul;4(7):101855.
doi: 10.1016/j.jacadv.2025.101855. Epub 2025 May 29.

Advanced Subclinical Atherosclerosis and Low-Dose Aspirin: Guideline-Based Extension Into Asymptomatic Chronic Coronary Syndromes

Michael J Blaha  1 , Francesca Santilli  2 , Dirk Sibbing  3 , Augusto Lavalle Cobo  4 , Magdy Abdelhamid  5 , Gerhard Albrecht  6 , Li Li  7
Affiliations
Editorial

Advanced Subclinical Atherosclerosis and Low-Dose Aspirin: Guideline-Based Extension Into Asymptomatic Chronic Coronary Syndromes

Michael J Blaha et al. JACC Adv. 2025 Jul.
No abstract available

Keywords: aspirin; asymptomatic chronic coronary syndrome; atherosclerosis; coronary artery disease.

PubMed Disclaimer

Conflict of interest statement

Funding support and author disclosures Dr Blaha is a member of advisory boards: Novo Nordisk, Novartis, Bayer, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Idorsia, Genentech, Agepha, Vectura, and New Amsterdam. Received grants from NIH, FDA, AHA, Novo Nordisk, Bayer, Amgen. Dr Santilli is a member of a Bayer AG global advisory board that convenes to discuss risk assessment and preventive pharmacotherapy in primary and secondary prevention. Dr Sibbing receives speaker fees and fees from advisory board activities from Bayer, Sanofi, and Daiichi Sankyo. Dr Cobo is a member of a Bayer AG global advisory board that convenes to discuss risk assessment and preventive pharmacotherapy in primary and secondary prevention. Received speaker honoraria from Novartis, Novo Nordisk, AstraZeneca, and Servier. Dr Abdelhamid is a member of a Bayer AG global advisory board that convenes to discuss risk assessment and preventive pharmacotherapy in primary and secondary prevention. Received speaker honoraria from Bayer, Novartis, AstraZeneca, and Pfizer. Dr Albrecht is an employee of Bayer. Dr Li is an employee of Bayer.

Figures

None
Graphical abstract
Figure 1
Figure 1
Correlation Between Asymptomatic Chronic Coronary Syndrome, Advanced Subclinical Atherosclerosis, and Low-Dose Aspirin ACS = acute coronary syndrome; ANOCA = angina with no obstructive CAD; CABG = coronary artery bypass graft; CAC = coronary artery calcium; CAD = coronary artery disease; CCS = chronic coronary syndrome; CCTA = coronary computed tomography angiography; CPS = carotid plaque ultrasound; ESC = European Society of Cardiology; INOCA = ischemia with no obstructive CAD; LV = left ventricular; PCI = percutaneous coronary intervention.
See this image and copyright information in PMC

References

    1. Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415–3537. - PubMed
    1. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. - PubMed
    1. Pontone G., Rossi A., Guglielmo M., et al. Clinical applications of cardiac computed tomography: a consensus paper of the European Association of Cardiovascular Imaging-part I. Eur Heart J Cardiovasc Imaging. 2022;23(3):299–314. - PMC - PubMed
    1. Dzaye O., Razavi A.C., Blaha M.J., Mortensen M.B. Evaluation of coronary stenosis versus plaque burden for atherosclerotic cardiovascular disease risk assessment and management. Curr Opin Cardiol. 2021;36(6):769–775. - PMC - PubMed
    1. Fuster V., García-Álvarez A., Devesa A., et al. Influence of subclinical atherosclerosis burden and progression on mortality. J Am Coll Cardiol. 2024;84(15):1391–1403. - PubMed

Publication types